Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

STELLAR – Final results of a phase 2 trial of TTFields with chemotherapy for first line treatment of pleural mesothelioma

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Federica Grosso

Citation

Annals of Oncology (2018) 29 (suppl_8): viii641-viii644. 10.1093/annonc/mdy301

Authors

F. Grosso1, J.G. Aerts2, J. Madrzak3, R. Dziadziuszko3, R. Ramlau4, S. Cedres5, B. Hiddinga6, J.P. van Meerbeeck6, M. Mencoboni7, D. Planchard8, A. Chella9, L. Crino10, M.J. Krzakowski11, G.L. Ceresoli12

Author affiliations

  • 1 Oncology, SS Antonio e Biagio Hospital, Department of Oncology, Via Venezia 16, 15121 - Alessandria/IT
  • 2 Oncology, Erasmus University Medical Center, 3015 CE - Rotterdam/NL
  • 3 Oncology, Medical University of Gdansk Clinical Hospital, Gdansk/PL
  • 4 Oncology, Medical University of Poznan, Poznan/PL
  • 5 Oncology, Vall d’Hebron University Hospital, Barcelona/ES
  • 6 Oncology, Antwerp University Hospital, Antwerp/BE
  • 7 Oncology, Ospedale Villa Scassi, 16149 - Genova/IT
  • 8 Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 9 Oncology, Cisanello University hospital Pisa, 56124 - Pisa/IT
  • 10 Oncology, Ospedale S. Maria della Misericordia, 06156 - Perugia/IT
  • 11 Department Of Lung & Thoracic Tumours, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, 02-781 - Warsaw/PL
  • 12 Oncology, Humanitas Gavazzeni, 24125 - Bergamo/IT
More

Resources

Background

Tumor Treating Fields (TTFields) are an anti-mitotic, regional treatment modality, using low intensity alternating electric fields delivered non-invasively to the tumor using a portable, medical device. In vitro, human mesothelioma cells were highly susceptible to TTFields. TTFields have been shown to extend survival of patients with glioblastoma when added to chemotherapy.

Methods

The trial accrued 80 patients with unresectable, untreated mesothelioma. Patients were treated with continuous 150 kHz TTFields in combination with pemetrexed and platinum. Inclusion criteria included ECOG 0-1 and at least one measurable lesion according to modified RECIST. Patients were followed q3w (CT scan q6w) until disease progression. The primary endpoint was overall survival (OS). This single arm study assumed historical control with a median survival of 12.1 months (Vogelzang et al. 2003). The sample size provided 80% power with a two-sided alpha of 0.05 to detect an increase in median OS of 5.5 months.

Results

All patients had a minimum follow up of 12 months. Median age was 67 (range 27-78), 84% were male and 56% smokers. 16% (13 patients) had metastatic disease and 44% (35 patients) had an ECOG PS of 1. 66% (53 patients) had epithelioid histology. Compliance with TTFields was 68% (16.3 hours/day) during the first 3 months of therapy. Median OS was 18.2 months (95% CI 12.1-25.8) compared to 12.1 months in historical controls. Median PFS was 7.6 months (95% CI 6.7-8.6) compared to 5.7 months in historical controls. Partial responses were seen in 40.3% of patients and clinical benefit (PR+SD) was seen in 97.2% of patients. No device-related serious adverse events (AEs) were reported. Expected TTFields-related dermatitis was reported in 46% (37 patients). Only 4 patients (5%) had grade 3 dermatitis.

Conclusions

The study met its primary endpoint of significant extension of survival for previously untreated mesothelioma patients. Secondary efficacy endpoints were also improved compared to historical control. The study demonstrated no safety concerns for the combination of TTFields to the thorax with chemotherapy. These results support the addition of TTFields to chemotherapy in the first-line treatment of malignant pleural mesothelioma.

Clinical trial identification

NCT02397928.

Legal entity responsible for the study

Novocure.

Funding

Novocure.

Editorial Acknowledgement

Disclosure

J.G. Aerts: Advisory boards: BMS, MSD, Roche, AstraZeneca, Eli Lilly, Boehringer Ingelheim, Amphera; Stock owner: Amphera. R. Ramlau: Consultant: Novocure. All other authors have declared no conflicts of interest.

Resources from the same session

VSV-IFN_-NIS intratumoral (IT) injection: a first-in-human (FIH), phase 1 study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors

Presenter: Steven Powell

Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Resources:

Abstract

Vall d’Hebron Institute of Oncology (VHIO) Immuno-Oncology prognostic index (VIO): a new tool for improved patient (pt) selection in Phase 1 (Ph1) trials with Immune Checkpoint Inhibitors (ICI).

Presenter: Cinta Hierro

Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings